Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The start of mid-stage testing of PF-07081532 triggers a $10 million milestone payment to Sosei Heptares, which has been working with Pfizer on small-molecule drugs directed at G protein-coupled ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

Pfizer has fully exited its investment in UK-listed pharma group Haleon, selling off its remaining 7.3% stake for £2.5bn.

Pfizer has raised £2.5 billion by offloading its remaining 7.3% stake in Haleon, the Panadol and Sensodyne business it used ...

The collaboration with BioNTech, particularly with the mRNA COVID-19 vaccine, marked a milestone in Pfizer's pharmaceutical advancements. In recent years, the company also achieved significant ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

Pfizer still owns about 7.3% of the company making it the largest shareholder. GSK sold its remaining stake in May last year.

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...

Headed by Pfizer Inc. and BioNTech, the trial involves 40,000 participants worldwide. It seeks to determine the efficacy of a new mRNA vaccine against the virus. Exactly 4,875 doses of the lifesaving ...

David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer, resulting in this first sales milestone for the Asia Pacific ...